Is CING or CGEN more profitable?

Compugen has a net margin of 47.97% compared to Cingulate's net margin of 0.00%. Compugen's return on equity of 47.72% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -365.15% -158.55% Compugen 47.97% 47.72% 27.51%

Is CING or FATE more profitable?

Cingulate has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -365.15% -158.55% Fate Therapeutics -2,056.79% -58.89% -39.39%

Does the media refer more to CING or FATE?

In the previous week, Cingulate had 12 more articles in the media than Fate Therapeutics. MarketBeat recorded 16 mentions for Cingulate and 4 mentions for Fate Therapeutics. Cingulate's average media sentiment score of 0.78 beat Fate Therapeutics' score of 0.63 indicating that Cingulate is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cingulate 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TRDA or CING?

In the previous week, Cingulate had 9 more articles in the media than Entrada Therapeutics. MarketBeat recorded 16 mentions for Cingulate and 7 mentions for Entrada Therapeutics. Cingulate's average media sentiment score of 0.78 beat Entrada Therapeutics' score of 0.34 indicating that Cingulate is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cingulate 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, AVXL or CING?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anavex Life Sciences N/A N/A -$46.38M -$0.46 N/A Cingulate N/A N/A -$22.45M -$4.23 N/A

Is AVXL or CING more profitable?

Anavex Life Sciences' return on equity of -38.76% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -38.76% -35.01% Cingulate N/A -365.15% -158.55%

Does the media favor AVXL or CING?

In the previous week, Cingulate had 14 more articles in the media than Anavex Life Sciences. MarketBeat recorded 16 mentions for Cingulate and 2 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.93 beat Cingulate's score of 0.78 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cingulate 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Is CING or LENZ more profitable?

Cingulate has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. LENZ Therapeutics' return on equity of -46.82% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -365.15% -158.55% LENZ Therapeutics -519.30% -46.82% -43.32%

Cingulate (CING) Competitors

$4.56 +0.53 (+13.15%)

As of 12:06 PM Eastern

Compare

CING vs. CGEN, FATE, TRDA, AVXL, and LENZ

Should you buy Cingulate stock or one of its competitors? MarketBeat compares Cingulate with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cingulate include Compugen (CGEN), Fate Therapeutics (FATE), Entrada Therapeutics (TRDA), Anavex Life Sciences (AVXL), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry.

How does Cingulate compare to Compugen?

Cingulate (NASDAQ:CING) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Cingulate presently has a consensus target price of $28.33, indicating a potential upside of 521.35%. Compugen has a consensus target price of $5.00, indicating a potential upside of 131.48%. Given Cingulate's higher possible upside, research analysts plainly believe Cingulate is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Compugen has a net margin of 47.97% compared to Cingulate's net margin of 0.00%. Compugen's return on equity of 47.72% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
Compugen	47.97%	47.72%	27.51%

In the previous week, Cingulate had 15 more articles in the media than Compugen. MarketBeat recorded 16 mentions for Cingulate and 1 mentions for Compugen. Compugen's average media sentiment score of 0.93 beat Cingulate's score of 0.78 indicating that Compugen is being referred to more favorably in the news media.

Company	Overall Sentiment
Cingulate	Positive
Compugen	Positive

Compugen has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
Compugen	$72.76M	2.81	$35.34M	$0.37	5.84

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 4.3% of Cingulate shares are owned by insiders. Comparatively, 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cingulate has a beta of -0.85, suggesting that its stock price is 185% less volatile than the broader market. Comparatively, Compugen has a beta of 2.74, suggesting that its stock price is 174% more volatile than the broader market.

Summary

Compugen beats Cingulate on 12 of the 15 factors compared between the two stocks.

How does Cingulate compare to Fate Therapeutics?

Cingulate (NASDAQ:CING) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Cingulate has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

In the previous week, Cingulate had 12 more articles in the media than Fate Therapeutics. MarketBeat recorded 16 mentions for Cingulate and 4 mentions for Fate Therapeutics. Cingulate's average media sentiment score of 0.78 beat Fate Therapeutics' score of 0.63 indicating that Cingulate is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cingulate	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Fate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cingulate has a beta of -0.85, indicating that its share price is 185% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.53, indicating that its share price is 153% more volatile than the broader market.

Cingulate presently has a consensus price target of $28.33, indicating a potential upside of 521.35%. Fate Therapeutics has a consensus price target of $5.13, indicating a potential upside of 119.02%. Given Cingulate's stronger consensus rating and higher probable upside, equities research analysts plainly believe Cingulate is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 4.3% of Cingulate shares are owned by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cingulate has higher earnings, but lower revenue than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
Fate Therapeutics	$6.65M	41.02	-$136.32M	-$1.09	N/A

Summary

Cingulate and Fate Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Cingulate compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cingulate has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
Cingulate	N/A	-365.15%	-158.55%

Entrada Therapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.85, suggesting that its stock price is 185% less volatile than the broader market.

In the previous week, Cingulate had 9 more articles in the media than Entrada Therapeutics. MarketBeat recorded 16 mentions for Cingulate and 7 mentions for Entrada Therapeutics. Cingulate's average media sentiment score of 0.78 beat Entrada Therapeutics' score of 0.34 indicating that Cingulate is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cingulate	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Entrada Therapeutics presently has a consensus target price of $18.25, indicating a potential upside of 176.10%. Cingulate has a consensus target price of $28.33, indicating a potential upside of 521.35%. Given Cingulate's higher probable upside, analysts plainly believe Cingulate is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cingulate has lower revenue, but higher earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$5.74M	44.72	-$143.75M	-$3.99	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

Summary

Entrada Therapeutics beats Cingulate on 8 of the 15 factors compared between the two stocks.

How does Cingulate compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 4.3% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anavex Life Sciences' return on equity of -38.76% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Cingulate	N/A	-365.15%	-158.55%

In the previous week, Cingulate had 14 more articles in the media than Anavex Life Sciences. MarketBeat recorded 16 mentions for Cingulate and 2 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.93 beat Cingulate's score of 0.78 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cingulate	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Anavex Life Sciences presently has a consensus target price of $21.33, suggesting a potential upside of 702.01%. Cingulate has a consensus target price of $28.33, suggesting a potential upside of 521.35%. Given Anavex Life Sciences' higher probable upside, research analysts plainly believe Anavex Life Sciences is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Anavex Life Sciences has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.85, meaning that its stock price is 185% less volatile than the broader market.

Summary

Anavex Life Sciences beats Cingulate on 7 of the 12 factors compared between the two stocks.

How does Cingulate compare to LENZ Therapeutics?

Cingulate (NASDAQ:CING) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

41.3% of Cingulate shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 4.3% of Cingulate shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cingulate has higher earnings, but lower revenue than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
LENZ Therapeutics	$20.99M	10.52	-$82.13M	-$3.60	N/A

Cingulate currently has a consensus target price of $28.33, suggesting a potential upside of 521.35%. LENZ Therapeutics has a consensus target price of $29.80, suggesting a potential upside of 323.30%. Given Cingulate's higher probable upside, research analysts plainly believe Cingulate is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cingulate has a beta of -0.85, indicating that its share price is 185% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

In the previous week, Cingulate had 15 more articles in the media than LENZ Therapeutics. MarketBeat recorded 16 mentions for Cingulate and 1 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.90 beat Cingulate's score of 0.78 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cingulate	Positive
LENZ Therapeutics	Positive

Cingulate has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. LENZ Therapeutics' return on equity of -46.82% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

Summary

LENZ Therapeutics beats Cingulate on 9 of the 14 factors compared between the two stocks.

Get Cingulate News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CING vs. The Competition

Export

Metric	Cingulate	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$61.42M	$3.26B	$6.26B	$12.44B
Dividend Yield	N/A	2.33%	2.69%	5.30%
P/E Ratio	-1.08	17.75	22.35	24.23
Price / Sales	N/A	323.71	555.60	126.08
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	14.71	6.55	9.82	6.73
Net Income	-$22.45M	$24.20M	$3.56B	$336.97M
7 Day Performance	15.15%	-3.25%	-1.16%	0.79%
1 Month Performance	-15.08%	0.48%	3.85%	5.38%
1 Year Performance	14.57%	47.06%	27.33%	34.55%

Cingulate Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CING Cingulate	3.0843 of 5 stars	$4.56 +13.2%	$28.33 +521.3%	+1.3%	$61.42M	N/A	N/A	20	News Coverage Options Volume
CGEN Compugen	3.9765 of 5 stars	$2.68 -4.3%	$5.00 +86.6%	+50.7%	$253.39M	$72.76M	7.24	70
FATE Fate Therapeutics	3.6373 of 5 stars	$2.15 -4.4%	$5.13 +138.4%	+97.7%	$250.60M	$6.65M	N/A	550	Gap Down
TRDA Entrada Therapeutics	4.0734 of 5 stars	$6.45 -1.7%	$18.25 +182.9%	-18.4%	$250.39M	$25.42M	N/A	110
AVXL Anavex Life Sciences	2.0068 of 5 stars	$2.66 -1.1%	$21.33 +702.0%	-63.1%	$246.50M	N/A	N/A	40	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CING) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cingulate (CING) Competitors

CING vs. CGEN, FATE, TRDA, AVXL, and LENZ

How does Cingulate compare to Compugen?

Summary

How does Cingulate compare to Fate Therapeutics?

Summary

How does Cingulate compare to Entrada Therapeutics?

Summary

How does Cingulate compare to Anavex Life Sciences?

Summary

How does Cingulate compare to LENZ Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CING vs. The Competition

Cingulate Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cingulate (CING) Competitors

CING vs. CGEN, FATE, TRDA, AVXL, and LENZ

How does Cingulate compare to Compugen?

Do analysts prefer CING or CGEN?

Is CING or CGEN more profitable?

Does the media prefer CING or CGEN?

Which has preferable valuation and earnings, CING or CGEN?

Do institutionals and insiders have more ownership in CING or CGEN?

Which has more risk & volatility, CING or CGEN?

Summary

How does Cingulate compare to Fate Therapeutics?

Is CING or FATE more profitable?

Does the media refer more to CING or FATE?

Which has more volatility & risk, CING or FATE?

Do analysts prefer CING or FATE?

Do institutionals & insiders believe in CING or FATE?

Which has preferable earnings & valuation, CING or FATE?

Summary

How does Cingulate compare to Entrada Therapeutics?

Do institutionals and insiders believe in TRDA or CING?

Is TRDA or CING more profitable?

Which has more volatility & risk, TRDA or CING?

Does the media favor TRDA or CING?

Do analysts rate TRDA or CING?

Which has preferable valuation and earnings, TRDA or CING?

Summary

How does Cingulate compare to Anavex Life Sciences?

Which has stronger earnings & valuation, AVXL or CING?

Do institutionals & insiders have more ownership in AVXL or CING?

Is AVXL or CING more profitable?

Does the media favor AVXL or CING?

Do analysts prefer AVXL or CING?

Which has more volatility & risk, AVXL or CING?

Summary

How does Cingulate compare to LENZ Therapeutics?

Do insiders & institutionals have more ownership in CING or LENZ?

Which has preferable valuation and earnings, CING or LENZ?

Do analysts rate CING or LENZ?

Which has more volatility & risk, CING or LENZ?

Does the media refer more to CING or LENZ?

Is CING or LENZ more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CING vs. The Competition

Cingulate Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools